MarsBars/E+ via Getty Images
- FibroGen (NASDAQ:FGEN) said late Friday that its chief financial officer and chief medical officer are leaving the company due to budget cuts.
- The company said Chief Financial Officer Juan Graham will remain with the company until Dec. 15, while Chief Marketing Officer Dr. Deyaa Adib They will leave on November 1. Both were informed of their dismissal on August 30. According to a document filed with the SEC.
- FibroGen (FGEN) announced in late July that it would reduce its U.S. workforce by 75% due to disappointing clinical results from its pancreatic cancer drug candidate pamrevlumab.
- FibroGen (FGEN) shares closed down 8% on Friday.